I
Ilya Tsimafeyeu
Publications - 10
Citations - 401
Ilya Tsimafeyeu is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 338 citations.
Papers
More filters
Journal ArticleDOI
Challenges to effective cancer control in China, India, and Russia
Paul E. Goss,Kathrin Strasser-Weippl,Brittany L. Lee-Bychkovsky,Brittany L. Lee-Bychkovsky,Lei Fan,Lei Fan,Junjie Li,Junjie Li,Yanin Chavarri-Guerra,Pedro E.R. Liedke,C S Pramesh,Tanja Badovinac-Crnjevic,Yuri Sheikine,Yuri Sheikine,Zhu Chen,You-Lin Qiao,Z Shao,Yi-Long Wu,Daiming Fan,Louis W.C. Chow,Jun Wang,Qiong Zhang,Shiying Yu,Gordon C Shen,Gordon C Shen,Jie He,Arnie Purushotham,Richard Sullivan,Rajendra A. Badwe,Shripad Banavali,Reena Nair,Lalit Kumar,Purvish M. Parikh,Somasundarum Subramanian,Pankaj Chaturvedi,Subramania Iyer,Surendra S Shastri,Raghunadhrao Digumarti,Enrique Soto-Perez-de-Celis,Dauren Adilbay,Vladimir Semiglazov,Sergey Orlov,Dilyara Kaidarova,Ilya Tsimafeyeu,Sergei Tatishchev,Kirill D. Danishevskiy,Marc Hurlbert,Caroline Vail,Jessica St. Louis,A. Chan +49 more
TL;DR: The overall state of health and cancer control in each country is described and additional specific issues for consideration are described: for China, access to care, contamination of the environment, and cancer fatalism and traditional medicine; for India, affordability of care, provision of adequate health personnel, and sociocultural barriers to cancer control.
Journal ArticleDOI
Abstract CT106: Primary tumor response in T1aN0M0 renal cell carcinoma patients ineligible for surgery and treated with nivolumab and ipilimumab: Results from phase 2 pilot study
TL;DR: The activity of immunotherapy against primary tumor was limited in patients with T1aN0M0 RCC ineligible for surgical treatment and treatment with nivolumab and ipilimumab was safe in Patients with moderate and severe comorbidities.
Journal ArticleDOI
1695P Neutralizing anti-FGFR1 antibody as a combined partner of anti-PD-1 antibodies in tumor models
Ilya Tsimafeyeu,J.S. Smith,Wei Yin,Alessandro Rissi Fanelli,Anna Sergeevna Olshanskaya,D. Khochenkov +5 more
Journal ArticleDOI
[Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization].
Grigory A. Raskin,Marina S. Mukhina,Elena D. Kravtsova,Ilya Tsimafeyeu,S. A. Tyulandin,Natalia P. Belyak,M. A. Kleshchev,Rashida Orlova +7 more
TL;DR: In this paper , a comparative analysis of the expression and amplification of the FGFR2 gene in gastric cancer in primary tumors and metastases in the lymph nodes was conducted, and the antibody Abcam clone EPR24075-418 was found satisfactory for the immunohistochemical study.
Journal Article
Multicenter phase 2 study of intrapleural nivolumab in patients with metastatic non-small cell lung cancer and pleural effusion.
Ilya Tsimafeyeu,Vadim Goutnik,Igor Shrainer,Vladislav Iu Kosyrev,Anastasia Bondarenko,Igor A Utyashev +5 more
TL;DR: In this article , the authors evaluated the safety of intra-pleural nivolumab in cancer patients and concluded that a single intrapleural instillation at 40 mg was ineffective and well-tolerated in patients with metastatic NSCLC and pleural effusion.